BML-190 explained

BML-190 (Indomethacin morpholinylamide) is a drug used in scientific research that acts as a selective CB₂ inverse agonist.^[1] BML-190 is structurally derived from the NSAID indomethacin but has a quite different biological activity.^[2] The activity produced by this compound is disputed, with some sources referring to it as a CB₂ agonist rather than an inverse agonist;^{[3] [4]} this may reflect an error in classification, or alternatively it may produce different effects in different tissues, and more research is required to resolve this dispute.

Notes and References

1. New DC, Wong YH . BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates . FEBS Letters . 536 . 1–3 . 157–60 . February 2003 . 12586356 . 10.1016/S0014-5793(03)00048-6 . 38569901 . free .
2. Klegeris A, Bissonnette CJ, McGeer PL . Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor . British Journal of Pharmacology . 139 . 4 . 775–86 . June 2003 . 12813001 . 1573900 . 10.1038/sj.bjp.0705304 .
3. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V . Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation . Endocrinology . 141 . 1 . 118–26 . January 2000 . 10614630 . 10.1210/endo.141.1.7239 . free .
4. Scutt A, Williamson EM . 23624771 . Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors . Calcified Tissue International . 80 . 1 . 50–9 . January 2007 . 17205329 . 10.1007/s00223-006-0171-7 .